Compound Detail
CHEMBL651
METHADONE 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
Basic Information
| ChEMBL ID | CHEMBL651 |
| Name | METHADONE |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | USSIQXCVUWKGNF-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
12
Targets
13
Activities
3
Assay Types
27
PK Parameters
20
Publications
12
Known Names
20
Indications
Molecular Properties
309.4
MW (Da)
4.29
ALogP
2
HBA
0
HBD
20.3
PSA (Ų)
0.76
QED
0
Ro5 Violations
7
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1947 |
| Availability | Prescription |
| Chirality | Racemic |
Indications
Pain Substance-Related Disorders Cancer Pain Chronic Pain Cocaine-Related Disorders Cocaine-Related Disorders Heroin Dependence HIV Infections Neoplasms Neuralgia Neuralgia, Postherpetic Opioid-Related Disorders Opioid-Related Disorders Renal Insufficiency, Chronic Scoliosis Neonatal Abstinence Syndrome Peripheral Nervous System Diseases Restless Legs Syndrome Hepatitis C Premature Birth
ATC Classification
N02AC52
methadone, combinations excl. psycholeptics
Level 1: NERVOUS SYSTEM
Level 2: ANALGESICS
N07BC02
methadone
Level 1: NERVOUS SYSTEM
Level 2: OTHER NERVOUS SYSTEM DRUGS
Activity Summary
IC50 7 meas. best 8.39
Ki 5 meas. best 7.89
EC50 1 meas. best 4.36
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Mu-type opioid receptor CHEMBL233 | IC50 | 8.39 | 8.39 | 4.1 | 1 |
| Mu-type opioid receptor CHEMBL233 | Ki | 7.89 | 7.89 | 13.0 | 1 |
| Aldehyde oxidase 1 CHEMBL1641355 | Ki | 7.52 | 7.52 | 30.0 | 1 |
| Kappa-type opioid receptor CHEMBL237 | IC50 | 6.29 | 6.29 | 512.0 | 1 |
| Delta-type opioid receptor CHEMBL236 | IC50 | 5.96 | 5.96 | 1090.0 | 1 |
| D(3) dopamine receptor CHEMBL234 | Ki | 5.68 | 5.68 | 2110.0 | 1 |
| ATP-dependent translocase ABCB1 CHEMBL4302 | IC50 | 5.12 | 5.12 | 7500.0 | 1 |
| Voltage-gated inwardly rectifying potassium channel KCNH2 CHEMBL240 | IC50 | 5.01 | 5.01 | 9772.4 | 1 |
| Cytochrome P450 2B6 CHEMBL4729 | Ki | 5.0 | 5.0 | 10000.0 | 1 |
| Unchecked CHEMBL612545 | IC50 | 4.64 | 4.64 | 23000.0 | 1 |
| D(4) dopamine receptor CHEMBL219 | Ki | 4.58 | 4.58 | 26200.0 | 1 |
| Voltage-gated L-type calcium channel CHEMBL2095229 | IC50 | 4.43 | 4.43 | 37400.0 | 1 |
| Mas-related G-protein coupled receptor member X2 CHEMBL5849 | EC50 | 4.36 | 4.36 | 43651.6 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 1.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.3 | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 41.4 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 59.3 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 1.4 | mL.min-1.kg-1 | Homo sapiens |
| CL | 1.7 | mL.min-1.kg-1 | Homo sapiens |
| CL | 29.4 | mL.min-1.kg-1 | Macaca |
| CL | 0.3 | ml/min | Homo sapiens |
| CL | 0.09 | ml/min | Homo sapiens |
| CL | 0.08 | ml/min | Homo sapiens |
| CL | 0.06 | ml/min | Homo sapiens |
| CL | 0.7 | ml/min | Homo sapiens |
| CL | 0.6 | ml/min | Homo sapiens |
| CL | 0.5 | ml/min | Homo sapiens |
| CL | 0.3 | ml/min | Homo sapiens |
| CL | 14.33 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 5.22 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 0.006 | mL.min-1.kg-1 | Homo sapiens |
| CL | 0.001 | mL.min-1.kg-1 | Homo sapiens |
| F | 80.0 | % | Homo sapiens |
| Fu | 0.11 | - | Homo sapiens |
| Fu | 0.21 | - | Homo sapiens |
| Fu | 0.21 | - | Homo sapiens |
| MRT | 43.0 | hr | Homo sapiens |
| T1/2 | 31.0 | hr | Homo sapiens |
| T1/2 | 0.4167 | hr | Homo sapiens |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 23298862 | 10.1124/dmd.112.050625 | ADMET | 24 |
| 22685215 | 10.1124/dmd.112.045971 | Cytochrome P450 2B6 | 15 |
| 22194678 | 10.1371/journal.pcbi.1002310 | Hepatotoxicity | 14 |
| 16621936 | 10.1124/dmd.105.006619 | ADMET | 8 |
| 20070106 | 10.1021/jm901371v | Homo sapiens | 8 |
| - | 10.6019/CHEMBL4651402 | SARS-CoV-2 | 4 |
| 18426954 | 10.1124/dmd.108.020479 | ADMET | 4 |
| 28288109 | 10.1038/nchembio.2334 | Mas-related G-protein coupled receptor member X2 | 4 |
| 660594 | 10.1021/jm00203a014 | Rattus norvegicus | 4 |
| 20014752 | 10.1021/tx900326k | Hepatotoxicity | 3 |
| 26948801 | 10.1016/j.drudis.2016.02.015 | Homo sapiens | 2 |
| 11408360 | - | ATP-dependent translocase ABCB1 | 2 |
| 23139379 | 10.1124/dmd.112.049312 | Rattus norvegicus | 2 |
| 19445515 | 10.1021/jm900403j | Homo sapiens | 2 |
| 966252 | 10.1021/jm00230a015 | Mus musculus | 2 |
| 7097722 | 10.1021/jm00348a016 | Mu-type opioid receptor | 2 |
| 10891117 | 10.1021/jm0000564 | No relevant target | 2 |
| 23139379 | 10.1124/dmd.112.049312 | ADMET | 2 |
| 14971904 | 10.1021/jm030408h | ADMET | 2 |
| 22328583 | 10.1124/dmd.111.043505 | Cytochrome P450 2J2 | 2 |
Data from ChEMBL 36 via Core Engine